All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is an independent medical education platform, supported by educational grants. We would like to express our gratitude to the following companies for their support: UCB, for website development, launch, and ongoing maintenance; UCB, for educational content and news updates. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View psoriasis and psoriatic arthritis content recommended for you
NP30179 phase I/II study: Fixed-duration glofitamab in R/R MCL
In total, 60 patients with R/R MCL and ≥1 previous line of therapy received obinutuzumab pretreatment (1,000 or 2,000 mg) 7 days before the first glofitamab dose. Glofitamab SUD was administered in Cycle 1 (Days 8 [2.5 mg] and 15 [10 mg]), with a Cycle 2 onward target dose of 16 mg or 30 mg Q3W for 12 cycles. Study outcomes included investigator-assessed CR rate and ORR, DoCR, DoR, PFS, OS, and safety.
|
Key learnings |
The investigator-assessed CR rate was 78.3%, with an ORR of 85.0%, a median DoCR of 15.4 months, and median DoR of 16.2 months. The median PFS and OS were 16.8 months and 29.9 months, respectively; 12-month PFS and OS were 56.7% and 73.9%, respectively. |
Patients previously treated with BTKi had lower response rates (CR: 71.0%, ORR: 74.2%) vs BTKi-naïve patients (CR: 86.2%, ORR: 96.6%). |
All patients had ≥1 AE; the most common were CRS (70.0%), neutropenia (38.3%), COVID-19 (31.7%), and pyrexia (31.7%). Grade 3/4 AEs and SAEs occurred in 65.0% and 78.3% of patients, respectively. CRS was more frequent with obinutuzumab pretreatment 1,000 mg vs 2,000 mg (87.5% vs 63.6%). |
Results from the phase I/II NP30179 trial showed high CR rates, durable responses, and a manageable safety profile of fixed-duration glofitamab in patients with R/R MCL, including in BTKi-pretreated patients, supporting further evaluation in phase III trials. |
Abbreviations: AE, adverse event; BTKi, Bruton tyrosine kinase inhibitor; CAR, chimeric antigen receptor; CR, complete response; CRS, cytokine release syndrome; DoCR, duration of CR; DoR, duration of response; MCL, mantle cell lymphoma; PFS, progression-free survival; ORR, overall response rate; OS, overall survival; Q3W, once every 3 weeks; R/R, relapsed/refractory; SAE, serious adverse event; SUD, step-up dosing.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?
